Skip to Main Content

Paper Details

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
J Immunother Cancer
0
2023
Author NameAffiliation
Evan Y YuUniversity of Washington
Evan Y YuClinical Research Division, Fred Hutchinson Cancer Center
  • 1 - 2

Datasets

Release 1.2